News

More information can be found on the settlement here.

CAMDEN, NJ, Aug. 1, 2017 – A Japanese pharmaceutical company, Daiichi Sankyo, will pay $300 million to settle thousands of federal and state court lawsuits over its top-selling blood pressure drugs, Benicar, Benicar HCT, Azor and Tribenzor, according to an announcement made today by the lead Plaintiffs’ lawyers in U.S. federal district court.

In a new safety alert, the FDA is warning of a dangerous risk of leg and foot amputations stemming from canagliflozin, the active ingredient in both Invokamet and Invokana, two widely used diabetes drugs. The FDA released the safety alert after reviewing the final results from two different clinical trials that looked at the drugs and their long-lasting effects over a large sample of patients suffering from type 2 diabetes.

The team at Pendley, Baudin & Coffin is currently investigating cases involving injury to infants and children from Hyland’s homeopathic teething tablets and gels.

PBC is pleased to announce that its own Chris Coffin has been appointed to the Plaintiffs' Steering Committee that will take the lead on all federal Taxotere litigation for plaintiffs throughout the U.S.

Taxotere, a chemotherapy drug manufactured by Sanofi-Aventis and primarily used to treat breast cancer, is linked to permanent hair loss or "alopecia" in women who were undergoing treatment for breast cancer.

Class members who submitted timely and valid claims for the pediatric Celexa, Lexapro settlement began receiving checks on June 27, 2016.  The class action accused Celexa and Lexapro manufacturer, Forest Laboratories, of improperly marketing the medications to minors under the age of 18.  The plaintiffs are represented by Baum, Hedlund, Aristei & Goldman, PC and Pendley, Baudin & Coffin, L.L.P.  Click here to read more.

Law360, New York (May 9, 2016, 4:05 PM ET) -- Health care fund providers seeking to recover money lost because of Forest Laboratories' allegedly fraudulent promotion of its drugs in treating pediatric depression pressed a Massachusetts federal judge to certify their portion of the multidistrict litigation as a class, saying previous court rulings and

Chris Coffin of Pendley, Baudin & Coffin was a speaker at a Taxotere Hair Loss Litigation Webinar held Thursday, March 10, 2016.  Lawyers litigating Taxotere cases presented a range of topics.  Included were overview of the case, intake, Taxotere toxicity and causation, state of the litigation, all about Sanofi Aventis, generic vs. brand name, etc.

Chris Coffin appointed Co-Lead Counsel and a member of the Plaintiffs' Executive Committee in the Benicar (Olmesartan) Products Liability Litigation.

Pendley, Baudin & Coffin is currently evaluating cases involving Benicar (Olmesartan medoxomil), Azor and Tribenzor, medications prescribed for the treatment of hypertension (high blood pressure). These drugs can result in sprue-like enteropathy which is a gastrointestinal problem. Users may have suffered years of chronic diarrhea, vomiting, severe pain and weight loss. Many of the side effects resemble symptoms of Celiac Disease.